Epithelial-To-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fiction or Fact?
Journal Title: Pancreas – Open Journal - Year 2016, Vol 1, Issue 1
Abstract
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most aggressive and lethal tumors, representing the fourth most common cause of cancer death in the Western world, with an estimated incidence of more than 40,000 cases per year in the United States. Despite continuous progress in imaging, surgical techniques, intensive care, and chemotherapeutic approaches, the current overall 5-year survival is less than 6%.1,2
Authors and Affiliations
Nicoletta Gagliano
Keywords
Related Articles
- EP ID EP556410
- DOI 10.17140/POJ-1-e001
- Views 161
- Downloads 0
Evaluation of the Best Power Setting of Laser Waves in Pancreatic Surgery: ECHO ND-YAG Laser Ablation on Bovine Pancreatic Tissue
Background: Pancreatic surgery is one of the most difficult and life-threatening surgical therapy especially during necrotizing pancreatitis and advanced solid neoplasms. Aim of the study: To evaluate the possibility to...
β-cell Heterogeneity: The Key to β-cell Replacement Therapy
Cellular heterogeneity is crucial for organisms to adapt to their environmental changes. It provides the morphological, functional and molecular diversity that allows tissues and organs to respond to stressors and mainta...
PD-1/PD-L1 Blockade: A New Promising Therapy for the Treatment of Pancreatic Cancer?
Programmed cell death protein 1 (PD-1), a member of the CD28 family, is an immune-checkpoint receptor expressed on a variety of immune cells, such as T-cells, monocytes, B-cells, dendritic cells, and tumor-infiltrating l...
Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma
Despite significant effort and research funds, Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the deadliest diseases. This cancer is characterized by a distinct desmoplastic reaction that constitutes 80% of the t...
Epigenetic Alterations in Pancreatic Cancer
Pancreatic cancer is the fourth leading cause of cancer death and is predicted to be the second leading cause in a decade in the US. Despite more than 50 years of research and therapeutic development, pancreatic cancer s...